Sign Up to like & get recommendations! 0
Published in 2024 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2024.4129
Abstract: Importance Immune checkpoint inhibitors (ICIs) are recognized as revolutionary cancer therapies but have raised concerns about immune-related adverse events, including the development of autoimmune diseases. Objective To evaluate the psoriasis risk associated with the use… read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.1611
Abstract: This systematic review and meta-analysis evaluates the immune checkpoint inhibitor regimens used along with the incidence of adverse events reported in randomized clinical trials for treatment of advanced melanoma. read more here.
Sign Up to like & get recommendations! 1
Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.28627
Abstract: Key Points Question When compared with prior therapies, are immune checkpoint inhibitors for metastatic melanoma associated with development of second primary cancers? Findings In this cohort study of 5016 patients with metastatic melanoma between 2005… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.26252
Abstract: This systematic review and meta-analysis of randomized clinical trials involving patients with solid tumors assesses the association of immune checkpoint inhibitors with patient-reported quality of life. read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.52244
Abstract: This comparative effectiveness research study compares outcomes of first-line therapy with immune checkpoint inhibitors vs chemotherapy among patients who have metastatic colorectal cancer with high microsatellite instability, mismatch repair deficiency, and/or high tumor mutational burden. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.7722
Abstract: Key Points Question What is the association of the use of checkpoint inhibitors with the risk of neurological adverse events? Findings In this meta-analysis of 39 trials evaluating the use of checkpoint inhibitors to treat… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2021.0249
Abstract: Importance Encephalitis is a severe immune-related adverse event secondary to treatment with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) ranges from disease that resolves fully to lethal forms. Moreover, ICIs may unmask… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4942
Abstract: Importance Primary resistance to immune checkpoint inhibitors is observed in 10% to 40% of patients with metastatic colorectal cancer (mCRC) displaying microsatellite instability (MSI) or defective mismatch repair (dMMR). Objective To investigate possible mechanisms underlying… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13409
Abstract: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis are the main therapeutic option for patients with advanced non‐small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13675
Abstract: Immune checkpoint inhibitors (ICIs) have been introduced in breast cancer (BC) treatment and better biomarkers are needed to predict benefit. Circulating tumor cells (CTCs) are prognostic in BC, but knowledge is limited on CTCs in… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202200999
Abstract: Lack of adequate effector T cells infiltrated in tumor is one of the main problems in the failure of immune checkpoint blockade therapy (ICBT). Photodynamic therapy (PDT) induced acute inflammation can sensitize tumors and activate… read more here.